A Study of BA1202 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single-arm phase I study in patients with advanced solid
tumors which consists of a dose escalation part (Part A) and a dose extension part (Part B).
Part A aims to evaluate the safety and tolerability of BA1202, and determine the MTD. Part B
will also evaluate the preliminary efficacy of BA1202.